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Jackson et al1 reported on a cohort of heart failure patients and concluded that microvolt T-wave 
alternans (MTWA) testing has limited utility in this population. Of note, this assessment was 
made in the complete absence of any outcomes data.  The authors base their assessment on the 
fact that they deemed 318 of 648 patients to be ineligible for MTWA testing.  The ineligibility 
was primarily attributable to the 38% incidence of atrial fibrillation which they reported while 
noting that this incidence was substantially higher than the 23% incidence reported in two earlier 
studies.  Seventy-six patients were deemed ineligible for MTWA testing due to inability to 
exercise or continuous ventricular pacing.  The authors ignored the availability of pharmacologic 
and pacing protocols to test this latter group of patients. Moreover, patients who cannot exercise 
on a treadmill often are able to elevate their heart rate adequately for MTWA testing (over 105 
bpm) by means of isometric exercise or stepping in place.   
 
The authors also reported a 46% indeterminacy rate which is much higher than that reported for 
similar patients in recent studies (for example 12%2 and 21%3).  Of note, Jackson et al1 did not 
follow the recommended procedure of repeating the MTWA test in all patients who initially 
tested indeterminate, but repeated the test only in patients who were indeterminate due to 
excessive noise.  Repeating the MTWA test in all patients who initially test indeterminate has 
been found to reduce the indeterminacy rate by 59%2.  Of note, in the LVEF ≤ 35% population, a 
properly conducted MTWA test with an indeterminate result confers at least as high a risk of 
sudden cardiac death as a positive test (see below). 
 
While MTWA testing is not currently suitable for patients in atrial fibrillation, for the remaining 
patients with heart failure MTWA testing is a simple highly predictive non-invasive test.  
Merchant et al4 reported in a recent pooled analysis that of 1004 patients with ejection fraction ≤ 
35%, 40% tested positive, 21% indeterminate, and 39% negative.  The corresponding annual 
rates of sudden cardiac death (SCD) were 4.0%, 4.6% and 0.9%. No study has shown a benefit 
for ICD therapy in a population with an annual SCD rate anywhere close to 0.9%.  ICD 
implantation itself is associated with an in-hospital mortality of 1% and a high rate of subsequent 
complications5.  Moreover, ICD therapy confers a mortality benefit only in patients with a non-
negative MTWA result and not in patients with a negative result6. 
 
MTWA testing can be used as a reliable tool to guide arrhythmic therapy in heart failure patients. 
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